Anti-cancer drug begins human trials
An anti-cancer drug developed by a UB faculty researcher and Kinex Pharmaceuticals has begun clinical testing with patients. The drug was created from the work of David Hangauer, UB associate professor of chemistry, who developed a compound that targets a protein linked to the survival of cancer cells. “We have the first success to come from this approach,” said Hangauer, who also serves as Kinex senior vice president of research and development. “Our drug compound has been shown to be active against all cancers.” Read more.
